NCT06601127View on ClinicalTrials.gov

Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

PHASE2RecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

February 21, 2025

Primary Completion Date

April 1, 2026

Study Completion Date

June 1, 2026

Conditions
Ischemic Stroke
Interventions
DRUG

Tiprogrel

Day 1, loading dose of tiprogrel and loading dose of aspirin; Day 2-90, daily maintenance dose of tiprogrel and daily maintenance dose of aspirin.

DRUG

Tiprogrel

Drug: Tiprogrel and Aspirin Day 1, loading dose of tiprogrel and loading dose of aspirin; Day 2-90, daily maintenance dose of tiprogrel and daily maintenance dose of aspirin.

DRUG

Clopidogrel

Day 1, loading dose of Clopidogrel and loading dose of aspirin; Day 2-21, daily maintenance dose of Clopidogrel and daily maintenance dose of aspirin; D22-90: daily maintenance dose of Clopidogrel.

Trial Locations (2)

Unknown

RECRUITING

Central Hospital Affiliated to Shenyang Medical College, Shenyang

NOT_YET_RECRUITING

Beijing Tiantan Hosptial, Capital Medical University, Beijing

All Listed Sponsors
lead

Tianjin Institute of Pharmaceutical Research Co., Ltd

OTHER_GOV